Continue to support Medicare's ability to negotiate drug prices.

Suhas Subramanyam · Virginia · Democratic

policy impact 0.72 specificity 0.81 extraction confidence 95%

Contest this claim

Occurrences

...and he will continue to support the ability of Medicare to negotiate drug prices.

Commits to supporting Medicare drug price negotiation.

Priorities — Suhas for Virginia
campaign · campaign_site · model gpt-5.4-mini

Evidence

"He fought for transparency in prescription drug pricing and won, and he will continue to support the ability of Medicare to negotiate drug prices. Suhas will stand up to Big Pharma and work to end the chronic disease epidemic."

Campaign issue page states Subramanyam previously fought for prescription drug price transparency and says he will continue to support Medicare drug-price negotiation.

unresolved same_term

Priorities — Suhas for Virginia
campaign · model gpt-5.4-mini · confidence 92%

Contest this evidence item

"In the Virginia House of Delegates (2019-2023) and the Virginia State Senate (2023-2024), Suhas passed landmark legislation to lower the costs of tolls, utility bills, and prescription drugs."

Official House site reflects an ongoing general record of lowering prescription drug costs, but it does not show a new Medicare drug-price negotiation action in the lookback window.

unresolved same_term

Representative Suhas Subramanyam | Home
secondary · model gpt-5.4-mini · confidence 68%

Contest this evidence item

Assessments

unresolved unknown

The promise is to continue supporting Medicare drug-price negotiation in federal office. The supplied evidence shows a campaign position and a general biography about prior prescription-drug cost work, but it does not document a House vote, cosponsorship, bill sponsorship, oversight action, public in-office statement, or other material federal action by Subramanyam after taking office that preserved or expanded Medicare negotiation authority. Because he is still in office and the record provided does not establish either delivery or failure, the claim remains unresolved rather than delivered or never fulfilled.

provider codex_cli · model gpt-5.5 · confidence 78%